The Pennant Group (PNTG) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
7 May, 2026Executive summary
Q1 2026 revenue reached $285.4 million, up 36% year-over-year, with adjusted EBITDA of $21.7 million, adjusted diluted EPS of $0.32, and net income of $8.5 million, driven by strong Home Health, Hospice, and Senior Living growth.
Growth was fueled by both organic expansion and acquisitions, with integration of large 2025 Southeast acquisitions progressing as planned and census rebounding above acquisition levels.
Leadership development remains a focus, with 47 new CEOs in training in 2026 and a robust pipeline for future growth.
Guidance for 2026 remains unchanged, but management points to the upper end of the range and expects continued operational improvements.
Net income attributable to shareholders rose to $8.5 million from $7.8 million in Q1 2025.
Financial highlights
GAAP revenue of $285.4 million, up $75.5 million or 36% year-over-year; adjusted EBITDA of $21.7 million, up 32.6%.
GAAP net income of $8.5 million, up $0.7 million or 9.6% year-over-year; adjusted net income of $11.5 million, up $1.9 million or 19.8%.
GAAP diluted EPS of $0.24, up $0.02 or 9.1%; adjusted diluted EPS of $0.32, up $0.05 or 18.5%.
Cash flows used in operations improved by $17.8 million year-over-year, with $4.9 million in cash on hand at quarter end.
Consolidated adjusted EBITDAR was $34.7 million, up 23.9% year-over-year.
Outlook and guidance
Guidance for 2026 remains unchanged, but management directs attention to the upper end of the range.
Management expects continued growth from acquisitions and organic expansion, with a focus on operational efficiency and margin improvement.
No immediate plans to adjust guidance until further progress is observed in integration and operational performance.
Expect continued same-store improvements and margin expansion as integration progresses.
Regulatory changes, reimbursement rates, and inflation remain key variables for future performance.
Latest events from The Pennant Group
- Record 2025 revenue and EPS growth, with 2026 guidance projecting further double-digit gains.PNTG
Q4 20251 Apr 2026 - Board recommends approval of all proposals, emphasizing governance and pay-for-performance.PNTG
Proxy filing31 Mar 2026 - Major acquisitions fuel growth, with integration and margin expansion as top priorities.PNTG
Oppenheimer 36th Annual Healthcare MedTech & Services Conference18 Mar 2026 - Expanding in the Southeast, leveraging local leadership, and preparing for regulatory changes.PNTG
Jefferies 2025 Healthcare Services Conference3 Feb 2026 - Q2 revenue up 27.6%, net income doubled, and guidance raised on strong segment growth.PNTG
Q2 20242 Feb 2026 - Q3 revenue up 28.9% to $180.7M, adjusted EPS $0.26, and guidance raised for 2024.PNTG
Q3 202415 Jan 2026 - Leadership-driven growth, payer diversity, and M&A fuel recovery and expansion amid regulatory shifts.PNTG
Stephens 26th Annual Investment Conference | NASH202413 Jan 2026 - Disciplined growth, leadership investment, and tech adoption drive strong outlook for 2025.PNTG
Oppenheimer 35th Annual Health Care MedTech and Services Conference26 Dec 2025 - Record 2024 revenue and net income growth, with double-digit gains expected in 2025.PNTG
Q4 20242 Dec 2025